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Summary Integrins are heterodimeric transmembrane proteins with large ectodomains and a short cytoplas-
mic tail inside the cell. They mediate cell adhesion to extracellular matrix proteins and to the surfaces of other
cells. In many cases the sequence recognised by the integrins in the extracellular matrix proteins is the
tripeptide Arg-Gly-Asp (RGD). Short synthetic peptides containing this sequence can inhibit invasion in vitro
and tumour dissemination in vivo. Thus, the asp, fibronectin binding integrin appears to be the key integrin in
the invasion of at least melanoma, osteosarcoma and glioblastoma cells. Modulation of the level and activities
of this integrin can suppress invasion, whereas the oc,3 vitronectin binding integrin appears to be associated
with increased invasiveness. There is increasing evidence that some of these effects are mediated through
signals elicited by the binding ofintegrins to their target proteins. This possibility has generated a great deal of
interest in the cytoplasmic molecules that might mediate the integrin-associated signalling.
Extracellular matrices can control cell motility and tumour
cell invasion by forming tissue barriers and by serving as
adhesive substrates. They also transmit signals to cells, both
directly through the receptors that mediate adhesion and
through growth factors and other cytokines bound to the
matrix.
It has been long suspected that cell adhesion plays an
important role in tumorigenicity and invasiveness. This
notion is based in part on the observation in the early 1970s
that fibronectin, a major component of the extracellular mat-
rix, was absent from the matrix of many tumorigenic cell
lines. Normal cells deposit an extracellular matrix around
themselves and then become anchored to it. Tumour cells
(and migrating embryonal cells) fail to deposit matrix, and
this allows such cells to remain less attached and more
mobile than normal cells. Thus, reinforced interaction of
tumour cells with matrix has an inhibitory effect on cell
proliferation and migration and converts the cells into non-
tumorigenic cells (Giancotti & Ruoslahti, 1990; Schreiner et
al., 1991). Moreover, the cell-cell adhesion molecule E-cad-
herin can curb the invasiveness of epithelial cells that express
it (Behrens et al., 1989; Chen & Obrink, 1991; Vleminckx et
al., 1991). Finally, a gene termed DCC that appears to
encode for an adhesion protein is lost in metastatic colon
cancer cells (Vogelstein et al., 1989), suggesting that DCC
also prevents cell invasion as well as possibly the relocation
of cells to distant sites.
While the observations discussed above establish a role for
cell adhesion in immobilising cells, it is clear that cell
adhesion can also promote migration of normal as well as
tumorigenic cells. Various kinds of cultured cells migrate on
extracellular matrix substrates and cell-matrix, and cell-cell
adhesion is thought to provide guidance and traction for cell
migration in vivo (see Ruoslahti & Pierschbacher, 1987).
Thus, for example, leukocytes lacking a group of integrin-
type cell adhesion receptors are incapable of moving from the
circulation into tissues (see Springer, 1990). Tumour dissem-
ination and invasion can be prevented with peptides that can
inhibit cell adhesion (Ruoslahti, 1991). It may be that strong
adhesion immobilises a cell but moderate adhesions is needed
for a cell to migrate (invade), because it provides the traction
necessary for movement. Alternatively, it may be that the cell
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adhesion receptors generate regulatory signals in cells and
that it is those signals that control cell migration and
invasion.
There is another important way extracellular matrices con-
trol cell behaviours. Increasing evidence suggests that many,
if not all, growth factors and cytokines are immobilised
through binding to extracellular matrices or to cell surfaces
(Ruoslahti & Yamaguchi, 1991).
This short review discusses some of the new developments
in the work dealing with the signalling aspect of cell-matrix
interactions mediated by the integrin family of adhesion
receptors.
Integrin-type adhesion receptors as signalling molecules
Integrins are a family of membrane glycoproteins consisting
of two subunits, a and P. Their properties have been exten-
sively reviewed (Hemler, 1990; Springer, 1990; Ruoslahti,
1991; Hynes, 1992). Thirteen integrin a subunits and eight P
subunits have been reported which, as far as it is known,
combine to form at least 19 different heterodimers (Figure 1).
The recognition site for many of the integrins that bind to
extracellular matrix and to platelet adhesion proteins is the
tripeptide Arg-Gly-Asp, or RGD (Ruoslahti & Pierschbacher,
1987). A peptide sequence entirely different from RGD
(GPEILDVPST) has been identified as the target sequence of
the 1413 integrin in the alternatively spliced CS-1 segment of
fibronectin (Mould et al., 1990; Guan & Hynes, 1990).
At least six of the known integrins function in an RGD-
dependent fashion (Figure 1). The remaining integrins are
likely to recognise other sequences, such as the one from the
CS-l segment.
The presence of multiple integrins endows a cell with the
capacity to recognise the cell's own extracellular matrix and
matrices secreted by other cells. This recognition system is
probably responsible for much of the positional information
cells need for anchorage, polarity, differentiation and directed
migration. Moreover, as discussed below, the ability of
tumour cells to invade also appears to depend on the inter-
action of integrins with their ligands.
Adhesion peptides inhibit tumour dissemination
Tumour cell migration through amniotic membrane tissue
can be inhibited with synthetic RGD peptides in an in vitro
tumour cell invasion assay (Gehlsen et al., 1988). This effect
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Figure 1 Integrin subunit combinations and the ligand specificities of the resulting integrin heterodimers. Coll, collagen; LM,
laminin; FN, fibronectin; Fn alt., fibronectin alternatively spliced domain; BM, basement membrane; FB, fibrinogen; vWF, von
Willebrand factor; ICAM, intercellular adhesion molecules; C3bi, complement component C3bi; FX, factor X. The relevant
references for most of the integrins in this scheme can be found in the reivews cited in the text. For the a046 binding specificity, see
Hynes, 1992, and for o7, a8, and P8, see Kramer et al., 1991, Bossy et al., 1991 and Moyle et al., 1991, respectively.
of the peptides in the invasion assay is receptor-specific;
peptides that inhibit the fibronectin receptor (C5PI integrin)
best are most active, whereas a peptide that inhibits the
vitronectin receptor (4vp3) better than the fibronectin receptor
(Pierschbacher & Ruoslahti, 1988) has much less of an effect
on the invasion. This is regardless of the fact that the test
cells possess the vitronectin receptor.
The RGD peptides can also affect tumour dissemination in
vivo. Several laboratories have published experiments in
which dissemination of intravenously injected tumour cells in
mouse tissues has been inhibited by a simultaneous injection
of an RGD peptide (Humphries et al., 1986; Tressler et al.,
1989; Saiki et al., 1989a,b). The dissemination and/or subse-
quent function of intravenously injected lymphocytes is also
inhibited by RGD peptides (Ferguson et al., 1991), suggest-
ing that a likely side effect of RGD peptide therapy might be
perturbance of some immune functions.
The mechanism whereby the RGD peptides inhibit tumour
invasion, dissemination and cell proliferation in the experi-
mental systems described above is not clear, but the effect
could be due to inhibition of cell adhesion. The loss of
adhesion would deny the cells anchorage as well as traction
for migration.
Another increasingly intriguing explanation is that the
binding of the peptide to the fibronectin receptors could
deliver a regulatory signal into the cells. That this could be
the case is suggested by several observations. Increasing evid-
ence from studies with lymphocytes, macrophages and other
cells shows that the PI integrins including MA participate in
signalling (Shimizu & Shaw, 1991; Schwartz et al., 1991).
This seems to apply to various types of tumour cells also.
Thus, cells grown in the presence of fibronectin are less
tumorigenic than those grown in the presence of laminin
(Terranova et al., 1984). Colon cancer cells respond to being
grown in a collagen gel by differentiating, an effect that
appears to be mediated by the a2P1 integrin (Pignatelli &
Bodmer, 1989). Moreover, tumorigenic cells lacking the X5P1
integrin are incapable of migrating even on surfaces where
this integrin plays no adhesive role (Bauer et al., 1992). The
migratory behaviour can be restored by reintroducing the
aI3, integrin through gene transfer.
In contrast, ligands of the a(03 integrin can enhance
tumour cell invasion in a basement membrane invasion assay
(Seftor et al., 1992). A possible mechanism for this effect is
the induction of proteolytic enzymes capable of degrading
extracellular matrix (Werb et al., 1989). Interestingly, an
elevated expression of the MCA3 integrin has been found to
coincide with the transition of melanomas into an invasive
mode (Albelda et al., 1990). These observations strongly
suggest the existence of an integrin-associated signalling
system in which the various integrins mediate distinct signals
(Figure 2). They also suggest ways of improving adhesion
peptide design.
Considering the effect of the avj3 integrin in invasion, an
ideal anti-invasive compound might be one that is specific for
the M5A1 integrin and affects it in such a manner that the
result for the cell is the same as the lack of this integrin in
the CHO cells. This would result in a migratory paralysis and
the effect would not be neutralised by an invasion-promoting
effect elicited through binding of the peptide to the OvP3
integrin. It is possible that the existing RGD peptides have
that kind of an effect because they not only inhibit tumour
cell (melanoma, glioma, sarcoma) invasion through amniotic
membranes (Gehlsen et al., 1988), but also through matrigel
(Seftor et al., 1992), which does not contain fibronectin.
These observations suggest two modes of RGD peptide
action in cancer therapy; they can be competitive inhibitors
of adhesion or deliver inhibitory signals by acting as integrin
agonists.
Possible mechanisms ofintegrin signalling
As discussed above, a vast body of evidence suggests that
integrin ligation does not only mediate adhesion but sends
signals into the interior of a cell. However, little is known
about what might happen inside the cell as a result of
integrin ligation. The integrin cytoplasmic tails are short
(30-50 amino acids) and their sequences give few clues as to
what molecules they might interact with. A possible excep-
tion is an alternatively spliced cytoplasmic domain of the PI
subunit we have found recently (Languino & Ruoslahti,
1992). It has some homology with the phosphotyrosine-
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Figure 2 Schematic representation of the influence of integrin expression on cell migration and invasion. (For details, see the text
and Giancotti & Ruoslahti, 1990, Bauer et al., 1992, and Seftor et al., 1992.)
binding sequence motif, SH2, which is present in many
regulatory proteins. Protein phosphorylation appears to be
involved, because several of the integrin subunits are phos-
phorylated (Hirst et al., 1986; Freed et al., 1989; Hibbs et al.,
1991; Hillery et al., 1991). Moreover, a 120-130 kDa protein
has been identified recently, the phosphorylation of which in
tyrosine residues occurs when cells spread on fibronectin
(Guan et al., 1991; Kornberg et al., 1991). This protein may
be present in the adhesion plaques where the fibronectin-
binding integrin is also concentrated when cells attach to a
fibronectin surface. The function of the 120-130 kDa protein
is not known, but it is a good candidate for mediating some
of the intracellular effects of fibronectin-induced (and per-
haps other) cell adhesion.
We have recently found a new protein, which we have
named peregrin, that is a also a possible messenger of signals
originating at the integrins (Thompson et al., unpublished
results). We discovered peregrin because it copurified with
the aJI integrin in affinity chromatography. Peregrin is a
nuclear protein that has several features in common with
various transcription factors; it may transmit signals from
alterations in cell adhesion to the nucleus.
Conclusion
Recent information on integrins suggests that, in addition to
serving as the physical 'hooks' for cell adhesion, they trans-
mit signals into cells. Much of the current work on integrins
is direced at deciphering the molecular workings of these
signalling events inside the cell. Two intracellular proteins
that may be important in this regard have been isolated and
others are undoubtedly in the pipeline. Progress in this area
of cell adhesion will make important contributions to the
understanding of contact inhibition and contact induction of
differentiation and is also likely to be helpful in the design of
cell adhesion-based approaches to anti-invasive tumour
therapies.
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